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Abstract
Background: A debilitating late effect for childhood cancer survivors (CCS) is cancer-related fatigue (CRF). Little is
known about the prevalence and risk factors of fatigue in this population. Here we describe the methodology of
the Dutch Childhood Cancer Survivor Late Effect Study on fatigue (DCCSS LATER fatigue study). The aim of the
DCCSS LATER fatigue study is to examine the prevalence of and factors associated with CRF, proposing a model
which discerns predisposing, triggering, maintaining and moderating factors. Triggering factors are related to the
cancer diagnosis and treatment during childhood and are thought to trigger fatigue symptoms. Maintaining factors
are daily life- and psychosocial factors which may perpetuate fatigue once triggered. Moderating factors might
influence the way fatigue symptoms express in individuals. Predisposing factors already existed before the
diagnosis, such as genetic factors, and are thought to increase the vulnerability to develop fatigue. Methodology of
the participant inclusion, data collection and planned analyses of the DCCSS LATER fatigue study are presented.
Results: Data of 1955 CCS and 455 siblings was collected. Analysis of the data is planned and we aim to start
reporting the first results in 2022.
Conclusion: The DCCSS LATER fatigue study will provide information on the epidemiology of CRF and investigate
the role of a broad range of associated factors in CCS. Insight in associated factors for fatigue in survivors
experiencing severe and persistent fatigue may help identify individuals at risk for developing CRF and may aid in
the development of interventions.
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Background
Childhood cancer survival rate has improved signifi-
cantly over the last few decades, with currently an
expected 5-year survival rate of more than 80% [1–3].
Unfortunately, survival does not come without conse-
quences of cancer treatment. Almost three quarters of
Childhood Cancer Survivors (CCS) suffers from late ef-
fects following cancer treatment which can occur years
or even decades after treatment [4]. A debilitating late
effect is Cancer-Related Fatigue (CRF) [5]. The National
Comprehensive Cancer Network (NCCN) has defined
CRF as a distressing, persistent, subjective sense of phys-
ical, emotional, and/or cognitive tiredness or exhaustion
related to cancer and/or cancer treatment that is not
proportional to recent activity and interferes with usual
functioning [6]. It differs from fatigue experienced by
healthy individuals; CRF is more severe, more distres-
sing, leads to disability and is less likely to be relieved by
rest [7]. In addition, CRF most likely has a negative
impact on quality of life (QoL) but thus far this has only
been investigated in subgroups of CCS [8, 9].
Previous literature did not establish consensus about
the prevalence and risk factors of CRF in CCS. A
systematic review investigating CRF in CCS showed a
wide range in prevalence rates (0–61.7%, n = 18,682)
[10]. In addition, a recently published guideline for the
surveillance of CRF in childhood, adolescent, and young
adult cancer survivors also showed a wide range of
prevalence rates (10–85%, n = 11,628) [11]. Both studies
stated that clinical and statistical heterogeneity of previ-
ous literature made it difficult to compare the results
and draw conclusions regarding CRF prevalence and risk
factors. To gain knowledge on the prevalence and
associated factors of CRF, a sufficiently large, systematic
and comprehensive multicenter collaborative project was
suggested [11].
Fatigue is a subjective, multifactorial symptom. Diverse
factors such as age, sex, mental status and health status
have, among others, been shown to influence fatigue
[12]. As these factors are closely related, it is desirable to
evaluate their relationship with fatigue following cancer
in a multivariable model. In this way, possible associations
between factors are taken into account and confounding is
corrected for. An example of such a model was presented
by Bower et al. [13], including diagnosis and treatment re-
lated factors and predisposing and maintaining factors to
investigate the role of neuro-immune reactions on CRF in
survivors of adult-onset cancer (ACS). Another multivari-
able model was presented by Koornstra et al. [14] to
investigate CRF in cancer patients and included a vast array
of associated factors among which were comorbidities,
medication use and tumor related factors. Both models
emphasize the importance of a multicausal and multidis-
ciplinary approach to investigate CRF. Studies using such
models to investigate associated factors of CRF have
focused on patients and survivors of adult-onset
cancer [13, 14]. In the current study we will focus on
CRF in CCS using a model which distinguishes be-
tween predisposing, triggering, maintaining and mod-
erating factors (Fig. 1).
Here, we describe the methodology of the Dutch
Childhood Cancer Survivor Late Effect Study on fatigue
(DCCSS LATER fatigue study). The aim of the DCCSS
LATER fatigue study is to examine the prevalence of
and factors associated with CRF in CCS, based on the
presented model. Also, the impact of CRF on QoL in
CCS will be investigated. This is the first study to use a
nationwide (Dutch) cohort including all tumor types to
investigate the role of a broad range of associated factors
of CRF in CCS. Combining these factors in one study
will hopefully increase the knowledge of CRF in CCS
and enable adequate identification of risk groups.
Methods
Study design
The DCCSS LATER fatigue study is a cross-sectional
study in a nationwide cohort of Dutch CCS. It is part of
the DCCSS LATER study which is a comprehensive,
multidisciplinary program for patient care and research
into various late effects in CCS. Where the DCCSS
LATER fatigue study focuses on fatigue as a late effect
in CCS, other DCCSS LATER sub-studies focus on sec-
ond primary malignancies, thyroid function, hormone
deficiency, metabolic syndrome, reproductive potential,
bone mineral density, sexuality and psychosexual devel-
opment, cardiovascular toxicity, renal effects, pulmonary
dysfunction, psychosocial consequences, splenic func-
tion, hyposalivation and benign sequalae. In all pediatric
oncology centers in the Netherlands data was collected
from patient files, questionnaires and during a visit at
the expert clinic for late effects following cancer (LATE
R outpatient clinic). During the visit, which took place
between 2017 and 2020, participants received regular
medical care and simultaneously data was collected for
the DCCSS LATER study. The DCCSS LATER fatigue
study was approved by the Medical Research Ethics
Committee of the Amsterdam University Medical Center
(registered at toetsingonline.nl, NL34983.018.10). The
study was carried out in accordance with the declaration
of Helsinki [15].
Objectives
The objectives of the DCCSS LATER fatigue study are
to 1) investigate the prevalence of CRF in a cohort of
CCS including all cancer types and 2) determine factors
which might be associated with CRF in CCS. This study
will provide an estimate of overall- and treatment
specific risks for CRF in CCS. This knowledge should
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enable identification of groups at risk for developing fa-
tigue following cancer treatment.
Current status of the study
At the moment of writing, data collection has already
finished. Currently, the data is being cleaned by data-
managers. The aim is to start with the analyses of the
data in 2021.
The study population
Participants of the DCCSS LATER fatigue study were in-
cluded from the DCCSS LATER cohort (n = 6165). This
is a nationwide cohort of five-year CCS diagnosed with
histologically confirmed malignancies [16] or Langerhans
cell histiocytosis before the age of 18 between January 1st
1963 and December 31st 2001 in the Netherlands. From
this cohort, CCS living in the Netherlands who were alive
on January 1, 2017, when the invitation process started,
were invited to participate (Fig. 2a). Participants gave
written informed consent (or their parents when aged
< 16 years, n = 3).
Controls
Siblings A control group consisting of siblings of
CCS were included which enables matching on many
unmeasured factors such as ethnicity, genetic back-
ground, culture, community, socioeconomic status
and family environment. Survivors who participated in
the study were asked to provide contact details of
Fig. 1 Hypothesized multivariable CRF model in CCS. Model showing associated factors of CRF divided into predisposing- (genetic factors and
blood biomarkers which are thought to impact the vulnerability to fatigue), triggering- (factors related to the cancer diagnosis and treatment
during childhood and are thought to trigger fatigue symptoms), maintaining- (daily life- and psychosocial factors which may perpetuate fatigue
once triggered) and moderating factors (factors which might influence the way fatigue symptoms express in individuals). Continuous lines:
factors that are hypothesized to be directly related to CRF. Dashed lines: factors that are hypothesized to possibly act as moderator or
confounder for other factors, but might also directly be related to CRF. BMI: Body Mass Index. * Included comorbidities are categorized into the
following main organ systems: Neoplasms, Cardiac-, vascular-, respiratory-, gastro-intestinal-, hepatobiliary-, renal and urinary tract-, endocrine-,
musculoskeletal-, ear-, eye-, nervous system-, and other conditions
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their siblings which were used to invite them to
participate. Siblings, who have not had cancer and
who can read and speak Dutch, and who gave written
informed consent, were approached to participate in
the sibling control group (Fig. 2b).
Population controls Data of Dutch population controls
participating in the Lifelines project will be used as a sec-
ond control group, since siblings may be affected by the
disease history of their brother or sister in some way.
These participants broadly represent the general Dutch
population. Lifelines is a multi-disciplinary prospective
population-based cohort study examining in a unique
three-generation design the health and health-related
behaviors of approximately 167,000 persons living in the
North East of The Netherlands [17]. It employs a broad
range of investigative procedures in assessing the
biomedical, socio-demographic, behavioral, physical and
psychological factors which contribute to health and
disease of the general population. When we start data
analysis for the DCCSS LATER fatigue study, Lifelines
data of approximately 90.000 participants will be made
available and will then be matched on age and sex with
the survivors. The Lifelines control group will be
substantially larger than the CCS study group, ensuring
sufficient power to analyze differences in prevalence
rates. Participants with a (self-reported) history of cancer
will not be included in this control group.
Data collection
Fatigue
The Checklist Individual Strength (CIS) [18], a 20-item
questionnaire, scored on a 7-point Likert Scale, was used
to assess fatigue severity. The CIS measures several
aspects of fatigue using the subscales fatigue severity
(CIS-fatigue; 8 items), concentration (5 items),
Fig. 2 Flowcharts. a: Flowchart of the CCS participants. b: Flowchart of the sibling participants. IC – no participation: Gave consent, however did
not participate. No/missing fat. Data: Did not complete the Checklist Individual Strength subscale fatigue (CIS-fatigue), or duration fatigue
symptoms was unknown. When only one item of the CIS-fatigue was missing, the missing value was imputed with the mean score of the other
seven items (n = 5 survivors and n = 3 siblings). Participants with two or more missing values on the CIS-fatigue were excluded
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motivation (4 items) and physical activity level (3 items).
The total score ranges from 20 to 140 where a higher
score corresponds with more problems in this area. The
CIS is a reliable and valid instrument for the assessment
of fatigue, with a score of 35 or higher on the CIS-fatigue
severity subscale (range 8–56) indicating severe fatigue,
which was validated in currently treated cancer patients
and ACS [19].
Triggering factors
Factors related to the cancer diagnosis and treatment
during childhood are thought to trigger fatigue. Informa-
tion about the diagnosis and cancer treatment was
collected by data-managers using a uniform and
standardized protocol [20]. Details comprise information
on treatment start and end dates, treatment type i.e. sur-
gery, chemotherapy (CT), radiotherapy (RT) and stem
cell transplantation (SCT), treatment dose of CT and RT
and RT location. All treatment data cover treatments for
the initial tumor and all recurrences plus RT boosts
when applicable. Survivors who received radiotherapy
will be categorized in groups dependent on the body
part which was irradiated. We will distinguish between
patients who received RT to the head, total body, spine,
thorax, abdomen/pelvic region, neck, upper extremities
and lower extremities (see Figure S1 in Additional file
1). Radiation-exposed volume to the head will be catego-
rized into three groups (full-cranial-, partial-cranial- and
no-cranial irradiation) following previously described
methodology [21] and all irradiated regions will add-
itionally be categorized according to dose tertiles. Survi-
vors who received chemotherapy will be categorized in
groups dependent on the specific agent they were given.
We will distinguish between patients who received
anthracyclines, platinum derivates, alkylating agents,
vinca alkaloids and antimetabolites. Agents will addition-
ally be categorized according to dose tertiles.
Moderating factors
Moderating factors might influence the way fatigue
expresses in individuals. For example, females who
received cancer treatment might experience different
consequences compared to men who received the same
cancer treatment. In that case, sex acts as a moderator
leading to the development of fatigue symptoms in
individuals who received cancer treatment. We believe
that several demographic- and cancer treatment related
factors (see Fig. 1, moderating factors) may act as a
moderator for other included factors and are therefore
presented as such in the hypothesized model (dashed
lines from moderating factors to other factors). How-
ever, these factors may also directly influence CRF
(dashed line from moderating factors directly to CRF).
The exact role of these variables is yet to be determined
and will be investigated by means of the planned ana-
lyses (see below). During the clinic visit, a questionnaire
asking about the participant’s demographic data (see
Table S1 in Additional file 1) was completed. Age at
diagnosis was collected and time since diagnosis was
calculated.
Predisposing factors
Of the possible predisposing factors of fatigue, here
the role of genetic factors will be studied. Genetic
factors are thought to increase the vulnerability to de-
velop fatigue. Venous blood samples were collected
from survivors (n = 1874) during the clinic visit after
overnight fastening and stored at − 80 degrees Celsius
for future evaluation. From participants of whom we
were not able to collect a blood sample and from sur-
vivors after allogeneic SCT, saliva samples were col-
lected. A genome-wide association study (GWAS) will
be carried out to identify genetic variants associated
with fatigue.
Maintaining factors
Maintaining factors are daily life- and psychosocial
factors which may perpetuate fatigue once triggered.
During the clinic visit, height and weight of the partici-
pants was measured to calculate their body mass index
(BMI). BMI will be categorized as follows: Underweight
(BMI < 18.5), normal weight (18,5 ≤ BMI < 25), over-
weight (25 ≤ BMI < 30), obesity (BMI ≥ 30). Grip strength
was measured using an analogue hand dynamometer.
Grip strength was shown to be a good reflection of a
person’s muscle strength in general [22, 23]. Grip
strength was measured four times (two times left arm,
two times right arm) and the mean score will be used as
an indication for muscle strength. Additionally, a general
health questionnaire containing items about the partici-
pant’s medical history and current medical state was
completed on paper prior to the clinic visit (see Table 1
in Additional file 1 for details). During the clinic visit,
completeness of this questionnaire was checked by one
of the research nurses and discussed with the participant
when a question needed clarification. Self-reported
health problems and comorbidities were validated by the
physician. Comorbidities will be categorized according
to previous published methodology [24] into main organ
system categories: Neoplasms, Cardiac-, vascular-, respira-
tory-, gastro-intestinal-, hepatobiliary-, renal and urinary
tract-, endocrine-, musculoskeletal-, ear-, eye-, nervous
system-, and other conditions. Inflammatory markers
(interleukin-1, interleukin-6, CRP) will be measured in the
venous blood samples which were collected during the
clinic visit. In addition, the following questionnaires were
completed digitally on a laptop during the clinic visit:
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TAAQOL To assess QoL, the TNO (Netherlands
Organisation for Applied Scientific Research) and AZL
(Leiden University Medical Centre) Questionnaire for
Adult’s Quality of Life (TAAQOL) was completed [25].
The TAAQOL contains twelve subscales (Gross motor
function, Fine motor function, Cognitive function, Sleep,
Pain, Social functioning, Daily activities, Vitality, Happi-
ness, Aggressiveness, Depressive moods) with a total of
45 items, each scored on a 4-point Likert scale. Crude
scale scores are linearly transformed to a 0–100 scale
with higher scores indicating better functioning. The
questionnaire has been validated in both the general
population as well as in patients with chronic diseases
[25, 26]. The impact of fatigue on the health related do-
mains of QoL in CCS will be reported on in a separate
study.
HADS The Hospital Anxiety and Depression Scale
(HADS) [27] was used to assess the level of psycho-
logical distress. It asks the participant about anxious and
depressive feelings in the past 4 weeks, each containing
seven items on a 4-point Likert scale. The HADS was
found to be able to assess symptom severity and case-
ness of anxiety disorders and depression in both somatic,
psychiatric and primary care patients, and in the general
population [28]. A cutoff score of ≥8 for both the anxiety
subscale and the depression subscale can be used to
identify possible cases [28]. The HADS was validated in
different age groups of the Dutch population [29].
RSES The Rosenburg Self-Esteem Scale (RSES) [30] was
used as a measure for self-esteem. It contains ten items,
each asking the participant about global self-worth on a
4-point Likert scale. The total score ranges from 10 to
40, where a higher score corresponds with a higher
self-esteem. The RSES shows satisfying psychometric
properties [31].
PSQI The Pittsburgh Sleep Quality Index (PSQI) [32]
was used to assess sleep quality. It assesses seven com-
ponents (subjective sleep quality, sleep latency, sleep
duration, sleep efficiency, sleep disturbance, use of sleep
medication and daytime dysfunction) which are scored 0
(no difficulty) to 3 (severe difficulty), making the total
score range from 0 to 21. Psychometric properties are
good and have been validated in several patient popula-
tions, including breast cancer patients [33, 34]. The
PSQI can be used to screen participants for the presence
of significant sleep disturbance with a cut-off score
greater than 5 discriminating between good and poor
sleepers [32].
Squash The Short Questionnaire to assess health- en-
hancing physical activity (SQUASH) [35] was used to
assess the participant’s physical activity level. It measures
how frequent, how intense and how long a participant
carried out a certain type of activity (physical activity
from and to work, physical activity at work, physical
activity during spare time and physical activity doing
household activities). The SQUASH is a valid instrument
for categorizing adults according to the Dutch physical
activity guideline [36].
ICQ The Illness Cognition Questionnaire (ICQ) was
used as an instrument to assess the participant’s illness
beliefs. It has 3 subscales (helplessness, acceptance and
perceived benefits) each consisting of six items measured
on a 4-point Likert scale, with a total score ranging from
18 to 72. Its psychometric properties were shown to be
sufficient in patients with chronic diseases such as
rheumatoid arthritis and multiple sclerosis [37] and in
parents of a child with cancer [38].
An overview of the data we have collected and how
the measures will be used to create the model parame-
ters is shown in Table S2 in Additional file 1.
This table also shows which parameters will be
available for each group of participants, i.e. CCS, sibling
controls and/or Lifelines controls. Survivors who were
willing to be involved in research, but who declined a
visit to the LATER outpatient clinic or who were not
able to come in, were invited to participate in the
questionnaire-part only which could be completed digit-
ally at home.
To examine possible selection bias in the group of sur-
vivors that agreed to participate in the DCCSS LATER
fatigue study, the following, anonymized, data of the sur-
vivors who declined to participate will be retained in the
central database: sex, decade of birth, childhood cancer
diagnosis, decade of diagnosis, treatment with chemo-
therapy and /or radiotherapy (yes/no).
Definition of fatigue
CRF, is thought to be related in time to the cancer diag-
nosis and treatment. However, to make the comparison
with fatigue in the control groups who have not had
cancer, the term CRF is not applicable. To enable a
comparison between CCS and controls, we will use the
term Chronic Fatigue (CF). For a reliable distinction
between cases and non-cases, it is important to use a
fatigue questionnaire with a validated cut-off score to
indicate severe fatigue. It is also important to take into
account the minimal duration of symptoms of at least 6
months which was proposed to define chronic fatigue
[39] and has been used in other populations as well
[8, 10, 40, 41].
We define CF as severe fatigue, indicated with a score
of 35 or higher on the CIS fatigue severity subscale [19],
which persists for at least 6 months. A question on
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symptom duration is part of the general health question-
naire, see Table S1 in Additional file 1.
Statistical analyses
To examine possible selection bias between study partic-
ipants and persons who declined to participate, inde-
pendent t-tests will be conducted to compare the groups
with respect to the variables sex, decade of birth, child-
hood cancer diagnosis, decade of diagnosis, treatment
with chemotherapy and /or radiotherapy (yes/no).
Prevalence rates of CF within the survivors and the
two control populations will be presented descriptively.
Logistic regression analysis will be done with CF (yes/
no) as dependent variable and group (CCS, siblings,
population controls) as independent variable to deter-
mine whether prevalence rates differ between groups.
To determine factors which might be associated with
CF in CCS, a multivariable logistic regression analysis will
be performed with CF as dependent variable and the
triggering, maintaining and moderating factors as inde-
pendent variables. The predisposing genetic factors will be
analyzed in a separate sub-study. Multivariable logistic
regression will produce an Odds Ratio (OR) for each
possible risk factor (OR with 95% CI will be presented).
Each group of factors will be entered as separate block of
independent variables in the analysis. Each block will be
analyzed both separately as well as in combination with
the other blocks to examine the association of all factors
with each other. In addition, structural equation modeling
(SEM) will be applied [42]. To analyze structural relation-
ships between factors we will apply both confirmatory
analyses, by assuming a particular structure between vari-
ables and testing whether this structure is supported by
the available data, and more exploratory analyses that
search over different structures in an attempt to detect po-
tential causal relationships [43, 44]. The analyses will be
carried out in all three study groups (with the factors
available for each specific group; CCS, sibling controls and
population controls) to examine if associated factors differ
between groups. We will test for multicollinearity.
IBM SPSS (IBM Corp. Released 2017. IBM SPSS
Statistics for Windows, Version 25.0. Armonk, NY: IBM
Corp) and R [45] will be used for the statistical analyses.
Results
Study population
Characteristics of the total DCCSS LATER cohort (n =
6165) can be found elsewhere [46]. Of this cohort, 4735
eligible CCS participants were invited to participate in
the DCCSS LATER study. Data of 1955 CCS and 455
siblings was collected. In the following months, data will
be checked on correctness and cleaned. Analysis of the
data is planned for 2021 and we aim to start reporting
the first results in 2022.
Expected results
We will report the prevalence of CF for CCS and two
control populations. Factors associated with CF in CCS
will be determined, distinguishing between predisposing,
triggering, maintaining and moderating factors as
presented in our model. Furthermore, we aim to create
certain profiles which will help identify CCS at-risk for
the development of CF.
Discussion
We presented the methodology of the DCCSS LATER fa-
tigue study which will investigate CF in a nationwide co-
hort of CCS. The study presents a model discerning
predisposing, triggering, maintaining and moderating fac-
tors of CF in CCS. Investigating a broad range of possible
associated factors in a single study using clearly defined
methods is expected to give insight into the prevalence
and associated factors of CF in CCS and will enable com-
parison with other studies. We hypothesize the prevalence
rate of CF in CCS to be around 25%. This number is based
on the combined prevalence rates of severe fatigue seen in
the included studies in the previous mentioned systematic
review [10] with CCS aged 16–71 years at assessment. A
pilot study conducted in a partly overlapping cohort of
Dutch CCS (unpublished data, Sylvia van Deuren et al.)
found a similar prevalence rate of CF using the Short Fa-
tigue Questionnaire [47, 48] to indicate CF.
In our study, the predisposing factors studied are
genetic factors that might be related to how sensitive a
person is to develop CF following cancer and its treatment
and might also influence the persistence of fatigue. Be-
cause of the massive scope of the GWAS in which we will
analyze these genetic factors, this will be done in a separ-
ate study. It is assumed that triggering factors are related
to the cancer diagnosis and treatment during childhood,
starting CF. Maintaining factors are daily life-, psycho-
social- and inflammatory factors that may perpetuate the
fatigue once triggered. Moderating factors might influence
the way CF expresses in individuals. In the current study
we included several demographic- and treatment related
factors which might possibly act as moderators. An over-
view of all factors is shown in Fig. 1, wherein all variables
are shown that are believed to be related to fatigue. This re-
lation can be direct (direct lines from factors to fatigue in
Fig. 1) or indirect (dashed lines between the factors in Fig.
1), for example as a confounder, moderator or mediator to
other variables. Using the presented model, we aim to in-
vestigate the precise contribution of all these variables to
CF in CCS. Below, we hypothesize on the potential associ-
ated factors described in the model.
Fatigue model
The fatigue model presented is hypothetical and based
on findings in the literature and on clinical experience in
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the LATER outpatient clinic. We hypothesize that the
presented factors all play a role in the development and/
or persistence of fatigue symptoms in CCS. We catego-
rized the factors in a way we think to be appropriate and
plausible. The precise role of each factor is yet to be ex-
amined. The model as presented in the current paper is
meant as a starting point to create an overview of all
possible associated factors. We aim, when the DCCSS
LATER fatigue study is finished, to present a directed
acyclic graph (DAG), a tool to help interpreting relation-
ships in research [49], including only those variables that
are directly related to CRF or act as a confounder, mod-
erator or mediator.
Predisposing factors
It is suggested that genetic mechanisms are involved in
subjective experiences such as fatigue in cancer survivors
[50]. For example, breast cancer survivors with fatigue
show higher expression of genes of the pro-inflammatory
system that are under control of the transcriptions factor
NF-κB, compared to non-fatigued survivors [51]. Identifi-
cation of genetic factors associated with CF in CCS will
aid to adapt treatment based on risk models predicting
susceptibility to specific late effects. Such approaches are
likely to get a more prominent role in survivor care in the
future [52]. In a follow up study we will investigate in de-
tail the relation between genetics and CF in CCS. Based
on the above mentioned prevalence rate, we will be able
to detect Odds Ratios of 1.6 or higher per allele (allele
frequency of 0.3), however with the exploratory approach
of the study we believe outcomes to still be interesting. In
addition, this dataset can be used for validation of previ-
ous findings in literature and can be the basis for meta-
GWAS with other similar cohorts.
Moderating factors
Several studies showed female sex to be associated with
fatigue [53–56], making it likely that such an association
will be present in CCS. Furthermore, age at diagnosis
can influence the occurrence and severity of late effects
[57, 58]. However, it is unknown whether age at diagno-
sis could influence the development of CF in particular.
A systematic review conducted in CCS suggests age at
diagnosis to not play a role in CF, however no pooled
conclusion could be made [10]. Also, little is known
about the relation between CF and age at assessment in
CCS. It is hypothesized that a higher age at assessment
is associated with CF as two studies showed higher
prevalence of fatigue in older age groups of survivors
compared to survivors of younger age [8, 59].
A meta-analysis in breast cancer survivors showed that
having a partner decreased the risk of fatigue [60]. A
questionnaire study focusing on demographic-, lifestyle-
and treatment factors conducted in the DCCSS cohort
showed marital status not to be related to CF (unpub-
lished data, Sylvia van Deuren et al.). We expect to find
similar results. All these variables can directly act on the
prevalence of CF or indirectly, via other variables such
as type of treatment or diagnosis, in which case they act
as moderator or confounder.
Triggering factors
Type and intensity of cancer treatment have been associ-
ated with an increased risk for the development of
several late adverse effects [61, 62]. A systematic review
by van Deuren et al. [10] included multiple studies in-
vestigating triggering factors for fatigue in CCS and con-
cluded that due to differences in study methodology, no
conclusion could be drawn. Previous mentioned ques-
tionnaire study (unpublished data, Sylvia van Deuren
et al.) focusing on demographic-, lifestyle- and treatment
factors conducted in the DCCSS cohort showed CCS
with CNS tumors to have higher odds for reporting CF
compared to other childhood diagnoses. In the current
study, we will investigate the association of diagnosis-
and treatment-related factors with CF in CCS in more
detail including all factors described in the CRF model.
We will not only examine the type of treatment (surgery,
RT, CT, SCT) but also the relation of treatment intensity
and RT location on fatigue. Using the proposed model,
we will be able to correct for multiple possible confound-
ing factors and by doing so, we will be able to elaborate
on the precise role of diagnosis- and treatment-related
factors in the development of CF in CCS.
Maintaining factors
Gielissen et al. [63] proposed maintaining factors to be
responsible for the persistence of fatigue, based on a
cognitive behavioral model of CRF in which it is
assumed that cognitions and behavior can maintain
fatigue. Factors such as, social functioning, illness cogni-
tions and sleep disturbances are topics addressed during
cognitive behavior therapy (CBT) which was shown to
be an effective therapy to reduce fatigue in ACS [63]. A
pilot study investigating CBT in CCS showed promising
results [64] and another study showed a substantial
overlap in cognitive behavioral factors that can maintain
fatigue between CCS and patients with chronic fatigue
syndrome or ACS [65]. This suggests that these factors
also might play an important role in maintaining CF in
CCS.
Physical and psychological comorbidities have also
been associated with fatigue. For example, Mulrooney
et al. [54] described that CCS with heart failure, pulmon-
ary fibrosis, depression or obesity reported more fatigue
and sleep disorders. Ho and colleagues [66] showed
fatigue to be related to depression in survivors of both
childhood- and adult onset cancer and Karimi et al. [67]
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investigated the relation between depression and fatigue
in CCS specifically and also showed a significant associ-
ation. In contrast to Goërtz et al. (unpublished data, Yv-
onne MJ Goërtz et al.), who showed that factors
associated with fatigue in several chronic conditions are
not disease specific, but generic. They suggest a trans-
diagnostic approach for understanding fatigue in
patients with chronic health conditions. Contributing to
these results, Nap-van der Vlist et al. [68] suggest a
trans-diagnostic approach in children with chronic con-
ditions as well. By including several comorbidity categor-
ies in the presented multi-factorial fatigue model, we
aim to determine the precise role of these health condi-
tions in perpetuating fatigue symptoms in CCS.
Physical activity levels were shown to be associated
with fatigue levels during a one-year follow-up in a
mixed cohort of childhood cancer patients and survivors
[69]. Muscle strength was suggested to be related to
fatigue in patients with advanced cancer [70]. In the
current study hand grip strength will be used as an indi-
cation for muscle strength [22]. We hypothesize physical
activity and muscle strength to be negatively correlated
with CF in CCS. Information about smoking and alcohol
consumption was not collected from the participants in
the current study and this is considered a limitation.
Previous studies suggest Inflammatory markers to play
a role in the experience of fatigue symptoms in (adult)
cancer patients [13, 71, 72]. However it remains un-
known whether these markers might still be related to
fatigue in CCS. Therefore inflammatory markers (inter-
leuking-6, interleukin-6 and CRP) are included in our fa-
tigue model to investigate their association with chronic
fatigue in CCS.
Above, we discussed multiple factors possibly associ-
ated with CRF in CCS and included them in a model.
We aimed to create a complete model but we acknow-
ledge that there are other factors not included in the
model that also might be associated with CRF and inter-
esting to investigate. Examples are traumatic events or
past history of mood disorders. Future studies might
consider including these factors.
Conclusion
Using the model as presented, the DCCSS LATER fa-
tigue study will provide information on the epidemiology
and associated factors of CF in CCS. With person-
centered care getting a more prominent role in the
health-care system, insight in possible risk factors for
survivors experiencing CF is of great interest to identify
individuals at risk for developing CF. Ultimately, this
study will hopefully contribute to the improvement of
current treatment protocols decreasing CF and improv-
ing quality of life in CSS.
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